The following analysts have issued research coverage on Protox Therapeutics. The opinions, estimates or forecasts regarding Protox's performance made by analysts are theirs alone and do not necessarily represent the opinions, forecasts or predictions of Protox or its management. Protox does not by its reference below or distribution imply its endorsement of or concurrence with such opinions, estimates or forecasts.

Versant Partners
Douglas W. Loe, Ph.D., MBA
dloe@versantpartners.com
416-849-5005

Jennings Capital Inc.
Shameze Rampertab, B.Sc., MBA, CA
shameze.rampertab@jenningscapital.com
416-304-2176

Fraser Mackenzie Limited
David Denduk, CFA
ddenduk@frasermackenzie.com
(416) 955-4777 x229

What's New

May 15, 2008
Protox Doses First Patient In Phase 2 BPH Clinical Trial

May 13, 2008
Protox Reports 2008 First Quarter Results

May 5, 2008
Protox Announces Private Placement

April 30, 2008
Protox Announces Collaboration with FDA

Events

BioFinance
Toronto Marriott Eaton Centre Hotel (Trinity IV room) - Toronto, ON

When: May 7, 2008 10:30a.m. EDT

Presenter: Dr. Fahar Merchant, President & CEO

Stock Quote

	LAST TRADE:	$0.73
	TRADE TIME:	3:43PM EST
	CHANGE:	$-0.02 (-2.67%)
	PREV CLOSE:	$0.75
	OPEN:	$0.75
	BID:	$0.72
	ASK:	$0.73